Seres Therapeutics

Tuya Smart showcased AI innovations at CES 2025, Mativ Holdings partnered with Chasm for transparent heating tech, Vision Marine teamed with Calip for marine battery cooling plates. IGM Biosciences restructured, Seres Therapeutics reported positive Phase 1b results, Aptose Biosciences began AML study dosing. Chevron started oil production in the Gulf, Clear Channel sold its Europe-North segment, Aimco sold Miami properties. Rocket Lab advanced in secure communications, QIAGEN got FDA clearance for a GI panel. LendingClub to release 2024 earnings, ImmuCell reported strong 2024 results, Gatos Silver achieved record production. Firehouse Subs plans Brazil expansion.

Ferring Pharma's phase 3 trial of RBX2660, a microbiome therapy for Clostridioides difficile infection, shows preliminary positive efficacy. The therapy, derived from healthy gut bacteria, aims to repopulate the GI tract and out-compete C. diff. Ferring plans to discuss regulatory filing with the FDA, highlighting the therapy's potential to reduce recurrent infections without antibiotics.

Seres Therapeutics (MCRB) will present at the 43rd Annual J.P. Morgan Healthcare Conference, focusing on SER-155, its lead program with Breakthrough Therapy designation for reducing bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transplant. The company seeks a partner to further develop SER-155 and other pipeline candidates for vulnerable populations.

Xilio Therapeutics appoints Caroline Hensley as chief legal officer, bringing extensive experience in biotechnology legal and compliance matters.

Seres Therapeutics announced its participation in the 43rd Annual Healthcare Conference, highlighting SER-155, a breakthrough therapy for reducing bloodstream infections in vulnerable populations. The company seeks partnerships to further develop SER-155 and other pipeline candidates, aiming to improve patient outcomes with novel live biotherapeutics.

Seres Therapeutics announced participation in the 43rd Annual J.P. Morgan Healthcare Conference, highlighting SER-155, a breakthrough therapy for reducing bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transplant. The company seeks a partner to further develop SER-155 and other pipeline candidates for vulnerable populations.

Seres Therapeutics received FDA breakthrough therapy designation for SER-155, aiming to reduce bloodstream infections in allo-HSCT patients. SER-155 showed significant reductions in BSIs, systemic antibiotic exposure, and febrile neutropenia in Phase 1b trials. The company plans to expand SER-155's development for various patient groups and seeks a partner to support its programme.

Seres Therapeutics received FDA breakthrough therapy designation for SER-155, aimed at reducing bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transplant. The designation is based on positive Phase Ib clinical trial outcomes, showing significantly lower bacterial bloodstream infections, shorter antibiotic treatment, and reduced febrile neutropenia.

Seres Therapeutics received FDA breakthrough therapy designation for SER-155, a live biotherapeutic aimed at reducing bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transplant for hematological malignancies. SER-155 also decreases infection and graft-versus-host disease risks. The designation is based on Phase Ib trial results showing significantly lower bacterial BSIs, shorter antibiotic treatment, and reduced febrile neutropenia.